BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 21266020)

  • 1. Three novel alternative splicing mutations in BCR-ABL1 detected in CML patients with resistance to kinase inhibitors.
    Ma W; Giles F; Zhang X; Wang X; Zhang Z; Lee TS; Yeh CH; Albitar M
    Int J Lab Hematol; 2011 Jun; 33(3):326-31. PubMed ID: 21266020
    [TBL] [Abstract][Full Text] [Related]  

  • 2. An intron-derived insertion/truncation mutation in the BCR-ABL kinase domain in chronic myeloid leukemia patients undergoing kinase inhibitor therapy.
    Laudadio J; Deininger MW; Mauro MJ; Druker BJ; Press RD
    J Mol Diagn; 2008 Mar; 10(2):177-80. PubMed ID: 18276770
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clonal distribution of BCR-ABL1 mutations and splice isoforms by single-molecule long-read RNA sequencing.
    Cavelier L; Ameur A; Häggqvist S; Höijer I; Cahill N; Olsson-Strömberg U; Hermanson M
    BMC Cancer; 2015 Feb; 15():45. PubMed ID: 25880391
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Resistance to imatinib in patients with chronic myelogenous leukemia and the splice variant BCR-ABL1(35INS).
    Berman E; Jhanwar S; Hedvat C; Arcila ME; Wahab OA; Levine R; Maloy M; Ma W; Albitar M
    Leuk Res; 2016 Oct; 49():108-12. PubMed ID: 27658269
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A thirty-five nucleotides BCR-ABL1 insertion mutation of controversial significance confers resistance to imatinib in a patient with chronic myeloid leukemia (CML).
    Marcé S; Cortés M; Zamora L; Cabezón M; Grau J; Millá F; Feliu E
    Exp Mol Pathol; 2015 Aug; 99(1):16-8. PubMed ID: 25913326
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In chronic myeloid leukemia patients on second-line tyrosine kinase inhibitor therapy, deep sequencing of BCR-ABL1 at the time of warning may allow sensitive detection of emerging drug-resistant mutants.
    Soverini S; De Benedittis C; Castagnetti F; Gugliotta G; Mancini M; Bavaro L; Machova Polakova K; Linhartova J; Iurlo A; Russo D; Pane F; Saglio G; Rosti G; Cavo M; Baccarani M; Martinelli G
    BMC Cancer; 2016 Aug; 16():572. PubMed ID: 27485109
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Detection of BCR-ABL1 kinase domain mutations causing imatinib resistance in chronic myelogenous leukemia.
    Moore FR; Yang F; Press RD
    Methods Mol Biol; 2013; 999():25-39. PubMed ID: 23666688
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Spectrum of BCR-ABL Mutations and Treatment Outcomes in Ethiopian Imatinib-Resistant Patients With Chronic Myeloid Leukemia.
    Tadesse F; Asres G; Abubeker A; Gebremedhin A; Radich J
    JCO Glob Oncol; 2021 Jul; 7():1187-1193. PubMed ID: 34292760
    [TBL] [Abstract][Full Text] [Related]  

  • 9. BCR-ABL1 kinase domain mutation analysis in an Irish cohort of chronic myeloid leukemia patients.
    McCarron SL; O'Connor LM; Langabeer SE; Conneally E
    Genet Test Mol Biomarkers; 2013 Feb; 17(2):170-3. PubMed ID: 23289634
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Persistent detection of alternatively spliced BCR-ABL variant results in a failure to achieve deep molecular response.
    Yuda J; Miyamoto T; Odawara J; Ohkawa Y; Semba Y; Hayashi M; Miyamura K; Tanimoto M; Yamamoto K; Taniwaki M; Akashi K
    Cancer Sci; 2017 Nov; 108(11):2204-2212. PubMed ID: 28801986
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Presence of novel compound BCR-ABL mutations in late chronic and advanced phase imatinib sensitive CML patients indicates their possible role in CML progression.
    Akram AM; Iqbal Z; Akhtar T; Khalid AM; Sabar MF; Qazi MH; Aziz Z; Sajid N; Aleem A; Rasool M; Asif M; Aloraibi S; Aljamaan K; Iqbal M
    Cancer Biol Ther; 2017 Apr; 18(4):214-221. PubMed ID: 28278078
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Recommendations from the French CML Study Group (Fi-LMC) for BCR-ABL1 kinase domain mutation analysis in chronic myeloid leukemia].
    Cayuela JM; Chomel JC; Coiteux V; Dulucq S; Escoffre-Barbe M; Etancelin P; Etienne G; Hayette S; Millot F; Nibourel O; Nicolini FE; Réa D;
    Bull Cancer; 2020 Jan; 107(1):113-128. PubMed ID: 31353136
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Implications of BCR-ABL1 kinase domain-mediated resistance in chronic myeloid leukemia.
    Soverini S; Branford S; Nicolini FE; Talpaz M; Deininger MW; Martinelli G; Müller MC; Radich JP; Shah NP
    Leuk Res; 2014 Jan; 38(1):10-20. PubMed ID: 24131888
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Recurrent Atypical e8a2 BCR::ABL1 Transcript with Insertion of an Inverted 55 Base Pair ABL1 Intron 1b Sequence: A Detailed Molecular Analysis.
    Burmeister T; Bullinger L; le Coutre P
    Acta Haematol; 2023; 146(5):413-418. PubMed ID: 37231781
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Molecular analysis of the BCR-ABL1 kinase domain in chronic-phase chronic myelogenous leukemia treated with tyrosine kinase inhibitors in practice: study by the Nagasaki CML Study Group.
    Itonaga H; Tsushima H; Imanishi D; Hata T; Doi Y; Mori S; Sasaki D; Hasegawa H; Matsuo E; Nakashima J; Kato T; Horai M; Taguchi M; Matsuo M; Taniguchi H; Makiyama J; Sato S; Horio K; Ando K; Moriwaki Y; Sawayama Y; Ogawa D; Yamasaki R; Takasaki Y; Imaizumi Y; Taguchi J; Kawaguchi Y; Yoshida S; Joh T; Moriuchi Y; Nonaka H; Soda H; Fukushima T; Nagai K; Kamihira S; Tomonaga M; Yanagihara K; Miyazaki Y
    Leuk Res; 2014 Jan; 38(1):76-83. PubMed ID: 24262285
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Genetic alterations in the BCR-ABL1 fusion gene related to imatinib resistance in chronic myeloid leukemia.
    Martínez-Castillo M; Gómez-Romero L; Tovar H; Olarte-Carrillo I; García-Laguna A; Barranco-Lampón G; De la Cruz-Rosas A; Martínez-Tovar A; Hernández-Zavala A; Córdova EJ
    Leuk Res; 2023 Aug; 131():107325. PubMed ID: 37302352
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A coiled-coil mimetic intercepts BCR-ABL1 dimerization in native and kinase-mutant chronic myeloid leukemia.
    Woessner DW; Eiring AM; Bruno BJ; Zabriskie MS; Reynolds KR; Miller GD; O'Hare T; Deininger MW; Lim CS
    Leukemia; 2015 Aug; 29(8):1668-75. PubMed ID: 25721898
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The landscape of BCR-ABL mutations in patients with Philadelphia chromosome-positive leukaemias in the era of second-generation tyrosine kinase inhibitors.
    Chien SH; Liu HM; Chen PM; Ko PS; Lin JS; Chen YJ; Lee LH; Hsiao LT; Chiou TJ; Gau JP; Yang MH; Liu CY
    Hematol Oncol; 2020 Aug; 38(3):390-398. PubMed ID: 32011024
    [TBL] [Abstract][Full Text] [Related]  

  • 19. BCR-ABL kinase domain mutations in tyrosine kinase inhibitors-naïve and -exposed Southeast Asian chronic myeloid leukemia patients.
    Wongboonma W; Thongnoppakhun W; Auewarakul CU
    Exp Mol Pathol; 2012 Apr; 92(2):259-65. PubMed ID: 22314255
    [TBL] [Abstract][Full Text] [Related]  

  • 20. New mutations detected by denaturing high performance liquid chromatography during screening of exon 6 bcr-abl mutations in patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors.
    Mascarenhas CC; Cunha AF; Miranda EC; Zulli R; Silveira RA; Costa FF; Pagnano KB; De Souza CA
    Leuk Lymphoma; 2009 Jul; 50(7):1148-54. PubMed ID: 19557636
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.